Business
BioMarin to Host Third Quarter 2020 Financial Results Conference Call and Webcast on Thursday, November 5 at 4:30pm ET
SAN RAFAEL, Calif., Oct. 22, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief
About this update from Biomarin Pharmaceutical Inc.
[{"type":"text","content":"SAN RAFAEL, Calif., Oct. 22, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, November 5, at 4:30 p.m. ET to discuss third quarter 2020 financial results and provide a general business update.\n\n \n \n \n \n \n \n\n \nDial-in Number U.S. / Canada Dial-in Number: (866) 502-9859International Dial-in Number: (574) 990-1362Conference ID: 3291898\nReplay Dial-in Number: (855) 859-2056Replay International Dial-in Number: (404) 537-3406Conference ID: 3291898\nInterested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.biomarin.com. A replay of the call will be archived on the site for one week following the call.\nAbout BioMarin\nBioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare genetic diseases. The company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.biomarin.com. Information on BioMarin's website is not incorporated by reference into this press release.\nContacts:\nInvestors \nMedia\nTraci McCarty \nDebra Charlesworth\nBioMarin Pharmaceutical Inc. \nBioMarin Pharmaceutical Inc.\n(415) 455-7558 \n(415) 455-7451\n \n\n\n\n View original content to download multimedia:http://www.prnewswire.com/news-releases/biomarin-to-host-third-quarter-2020-financial-results-conference-call-and-webcast-on-thursday-november-5-at-430pm-et-301157647.html\nSOURCE BioMarin Pharmaceutical Inc.","length":6958,"tagName":"div"}]